Please login to the form below

Not currently logged in
Email:
Password:

Sun/ Merck enter Indian diabetes deal

Merck has teamed up with Sun Pharmaceutical to co-market Merck's diabetes drugs sitagliptin and sitagliptin plus metformin in India

Merck (known as MSD outside the US and Canada) has teamed up with Sun Pharmaceutical to co-market Merck's diabetes drugs, sitagliptin and sitagliptin plus metformin, in India.

Sitagliptin is currently marketed outside India as Januvia, and sitagliptin plus metformin is marketed as Janumet.

Under the agreement, Sun Pharma will have the rights to market, promote and distribute the drugs under different brand names in India.

Financial details of the agreement were not disclosed.

K G Ananthakrishnan, managing director, Merck in India, described increasing access to the drugs as an "urgent need" with increasingly high rates of type 2 diabetes in India.

S Kalyanasundaram, CEO, Sun Pharma also commented on the deal: "Through this partnership, the reach of sitagliptin and sitagliptin plus metformin will be enhanced amongst doctors and patients in India, helping them efficaciously manage the disease."

Sitagliptin is an oral antihyperglycaemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.

Two of the scientists behind the drug's discovery were recently honoured by Pharmaceutical Research and Manufacturers of America (PhRMA) with its 2011 Discoverers Award.

26th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics